Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for some hematologic malignancies. As the overall number of survivors continues to increase, studies systematically examining outcomes in long-term survivors are needed. We studied the clinical and quality-of-life outcomes in HSCT recipients surviving 5 or more years from HSCT. Since 1993, 262 patients with hematologic malignancies received a T cell-depleted myeloablative HSCT from an HLA-identical sibling at a single center. Ninety-two survived beyond 5 years from HSCT (median follow-up 9.4 years, range: 5.1-15.3). Median age at transplantation was 35 years (range: 10-56). Twenty-two (24%) received a bone marrow transplant, and 70 (76%) received a peripheral ...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for some hematolog...
We analyzed the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) over the past 2...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
We assessed late mortality in 1479 individuals who had survived 2 or more years after allogeneic hem...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
AbstractThe number of survivors after allogeneic hematopoietic stem cell transplantation (HSCT) cont...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for some hematolog...
We analyzed the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) over the past 2...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment...
We assessed late mortality in 1479 individuals who had survived 2 or more years after allogeneic hem...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
AbstractThe number of survivors after allogeneic hematopoietic stem cell transplantation (HSCT) cont...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...
We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second all...